NRx Pharmaceuticals is undergoing a first-cycle review of an ANDA for ketamine, noting its strategic importance for the U.S. military and VA.
3 reports, 3 independent
Updated Nov 1
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
NRx Pharmaceuticals is undergoing a first-cycle review of an ANDA for ketamine, noting its strategic importance for the U.S. military and VA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA grants approval for preservative-free generic ketamine.1 source
NRx is seeking regulatory review for ketamine, highlighting its military and VA strategic value.1 source